Related Experiment Video

Updated: Feb 19, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.6K

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N Gide1,2, James S Wilmott1,2, Richard A Scolyer1,2,3

  • 1Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|November 12, 2017
PubMed

Insights

Immune checkpoint inhibitors show promise for metastatic melanoma, but primary and acquired resistance limit effectiveness. Understanding immune evasion mechanisms is crucial for developing new therapies.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Immune checkpoint inhibitors (ICIs) have transformed advanced melanoma treatment, offering durable responses and improved survival.
  • However, primary and acquired resistance to ICIs remain significant clinical challenges, hindering further therapeutic advancements.
  • Understanding the complex mechanisms of tumor immune evasion is essential for overcoming resistance.

Purpose of the Study:

  • To review the mechanisms of primary and acquired resistance to immunotherapy in melanoma.
  • To explore potential therapeutic strategies to prevent and overcome immunotherapy resistance.

Main Methods:

  • Literature review of primary and acquired resistance mechanisms in melanoma immunotherapy.
  • Analysis of the cancer immune cycle and signaling pathways involved in therapeutic resistance.

Main Results:

  • Primary and acquired resistance are driven by complex interactions within the tumor microenvironment and immune signaling pathways.
  • Current knowledge of resistance mechanisms is incomplete, necessitating further research.

Conclusions:

  • Overcoming immunotherapy resistance in melanoma requires a comprehensive understanding of immune evasion strategies.
  • Developing novel therapeutic approaches targeting resistance mechanisms is critical for improving patient outcomes.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.9K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K